---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:16:00.440845'
end_time: '2025-12-14T17:22:11.509904'
duration_seconds: 371.07
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: PLD4
  gene_symbol: PLD4
  uniprot_accession: Q96BZ4
  protein_description: 'RecName: Full=5''-3'' exonuclease PLD4 {ECO:0000305}; EC=3.1.16.1
    {ECO:0000250|UniProtKB:Q8BG07}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate
    synthase PLD4 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811};
    AltName: Full=Phospholipase D family member 4; AltName: Full=Phospholipase D4;'
  gene_info: Name=PLD4 {ECO:0000303|PubMed:30111894, ECO:0000312|HGNC:HGNC:23792};
    Synonyms=C14orf175; ORFNames=UNQ2488/PRO5775;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the phospholipase D family. .
  protein_domains: Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase.
    (IPR001736); PLDc_3 (PF13918)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 14
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96BZ4
- **Protein Description:** RecName: Full=5'-3' exonuclease PLD4 {ECO:0000305}; EC=3.1.16.1 {ECO:0000250|UniProtKB:Q8BG07}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD4 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811}; AltName: Full=Phospholipase D family member 4; AltName: Full=Phospholipase D4;
- **Gene Information:** Name=PLD4 {ECO:0000303|PubMed:30111894, ECO:0000312|HGNC:HGNC:23792}; Synonyms=C14orf175; ORFNames=UNQ2488/PRO5775;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the phospholipase D family. .
- **Key Domains:** Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase. (IPR001736); PLDc_3 (PF13918)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PLD4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PLD4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PLD4** (gene ID: PLD4, UniProt: Q96BZ4) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96BZ4
- **Protein Description:** RecName: Full=5'-3' exonuclease PLD4 {ECO:0000305}; EC=3.1.16.1 {ECO:0000250|UniProtKB:Q8BG07}; AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD4 {ECO:0000305|PubMed:39423811}; EC=3.1.4.- {ECO:0000269|PubMed:39423811}; AltName: Full=Phospholipase D family member 4; AltName: Full=Phospholipase D4;
- **Gene Information:** Name=PLD4 {ECO:0000303|PubMed:30111894, ECO:0000312|HGNC:HGNC:23792}; Synonyms=C14orf175; ORFNames=UNQ2488/PRO5775;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the phospholipase D family. .
- **Key Domains:** Diverse_PLD-related. (IPR050874); PLDc_3. (IPR032803); PLipase_D/transphosphatidylase. (IPR001736); PLDc_3 (PF13918)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PLD4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PLD4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PLD4** (gene ID: PLD4, UniProt: Q96BZ4) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity: The target is human PLD4 (gene symbol PLD4; UniProt Q96BZ4), a type II membrane protein and member of the phospholipase D superfamily. Structural and functional studies characterize PLD4’s luminal catalytic domain and its conserved PLD-family motifs (HKD/E), confirming alignment with the UniProt entry and the PLD family/domain annotations. The organism context is Homo sapiens. (yuan2024structuralandmechanistic pages 23-26, yuan2024structuralandmechanistic pages 1-5, singh2024pld3andpld4 pages 1-3)

Key concepts and definitions
- Protein family and domains: PLD4 belongs to the PLD superfamily and retains the canonical HxKxxxxD/E (HKD/E) catalytic motifs, arranged within a bilobal luminal domain that forms the catalytic center typical for PLD folds. Despite PLD-family homology, PLD4’s active site is adapted for endolysosomal catalysis, including nucleic-acid substrates. (Structure, 2024; https://doi.org/10.1016/j.str.2024.02.019) (yuan2024structuralandmechanistic pages 1-5)
- Enzymatic activities and substrate specificity:
  • Endolysosomal 5′→3′ exonuclease: PLD4 degrades single-stranded nucleic acids (ssDNA/ssRNA) from the 5′ end, limiting the availability of ligands for nucleic acid–sensing Toll-like receptors (e.g., TLR9). Biochemical assays showed cleavage of CpG ODN with phosphodiester linkages but not phosphorothioates; activity is pH-dependent and optimized for acidic endolysosomal conditions. (Structure, 2024; https://doi.org/10.1016/j.str.2024.02.019) (yuan2024structuralandmechanistic pages 1-5, yuan2024structuralandmechanistic pages 23-26)
  • S,S-BMP synthase (lysosomal lipid enzyme): In 2024, PLD4 (and PLD3) was shown to synthesize lysosomal S,S-bis(monoacylglycero)phosphate (S,S‑BMP) via a transphosphatidylation reaction using lyso‑phosphatidylglycerol (lyso‑PG) and monoacylglycerol (MAG) as substrates. Activity is favored at lysosomal pH and shows synergy when both lyso‑PG and MAG are available. S,S‑BMP is the stereochemically stabilized lysosomal BMP isomer that supports lipid catabolism. (Cell, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 3-5, singh2024pld3andpld4 pages 1-3)
  • Substrate specificity nuances: Structural data reveal PLD4 features a hydrophobic “clamp” (including L183/F423) near the catalytic site that influences 5′-end recognition and sterically limits some 5′-modified ssDNA substrates. For lipid synthesis, PLD4 selectively produces the S,S stereoisomer of BMP, which is more resistant to lysosomal degradation than other isomers. (Structure, 2024; https://doi.org/10.1016/j.str.2024.02.019; Cell, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (yuan2024structuralandmechanistic pages 14-17, singh2024pld3andpld4 pages 3-5)
- Cellular localization: PLD4 is synthesized as a type II transmembrane protein with an N‑terminal cytosolic tail and a luminal catalytic domain that traffics to endosomes/lysosomes, where its activities (nuclease and BMP synthase) occur. (Structure, 2024; https://doi.org/10.1016/j.str.2024.02.019; Cell, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (yuan2024structuralandmechanistic pages 23-26, singh2024pld3andpld4 pages 1-3)

Recent developments and latest research (emphasis 2023–2024)
- Structural and mechanistic insights (2024): High-resolution structures of human PLD4 (and mouse PLD3) solved in multiple states (apo, intermediate, product) define a PLD-family “link‑and‑release” ping‑pong catalytic mechanism for 5′ exonuclease activity, reveal the basic active-site environment, capture a covalent intermediate, and explain enzyme differences: PLD4’s hydrophobic clamp stabilizes the first base of the product and narrows substrate tolerance; PLD4 exhibits a lower pH optimum than PLD3, consistent with more acidic endolysosomal function. (Structure, 2024; https://doi.org/10.1016/j.str.2024.02.019) (yuan2024structuralandmechanistic pages 1-5, yuan2024structuralandmechanistic pages 14-17)
- Discovery of lysosomal S,S‑BMP synthase activity (2024): PLD4 and PLD3 were shown to be the enzymes that synthesize S,S‑BMP in lysosomes. Purified enzymes and cell-based systems demonstrated robust BMP production via transphosphatidylation (lyso‑PG + MAG), with loss of either enzyme causing tissue-specific BMP deficits and lysosomal lipid storage phenotypes; double loss is lethal, indicating partial redundancy. Many lysosomal defects were rescued by exogenous S,S‑BMP. (Cell, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 1-3, singh2024pld3andpld4 pages 7-8, singh2024pld3andpld4 pages 3-5)

Current applications and real-world implementations
- Lysosomal lipid metabolism and BMP homeostasis: The PLD4→S,S‑BMP axis is essential for intraluminal vesicle formation and lipid catabolism (e.g., gangliosides). In vivo, Pld4 knockout causes ≈80% BMP loss in spleen, with ≈2-fold accumulation of gangliosides and secondary lysosomal abnormalities (e.g., increased galectin‑3 recruitment, fewer intraluminal vesicles, modest reduction in protease activity; many phenotypes reversible by S,S‑BMP addition). These quantitative tissue lipidomics and rescue experiments provide a framework for BMP supplementation or enzyme/pathway modulation strategies as translational avenues. (Cell, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8)
- Endosomal nucleic-acid sensing pathway modulation: By degrading ss nucleic acids, PLD4 limits excessive TLR7/TLR9 activation, suggesting opportunities to modulate PLD4 activity (or downstream signaling) in autoimmune or inflammatory settings where nucleic-acid sensing is dysregulated. (Structure, 2024; https://doi.org/10.1016/j.str.2024.02.019) (yuan2024structuralandmechanistic pages 1-5)

Expert opinions and analysis from authoritative sources
- 2015 review perspective: Earlier work summarized PLD4 as a microglia/myeloid-enriched type II transmembrane protein with roles in phagocytosis and autoimmune phenotypes, but with uncertain enzymology. The 2024 studies resolve this by demonstrating dual functions: nuclease activity and lysosomal S,S‑BMP synthase activity, establishing PLD4 as both an immune-regulatory nuclease and a key lysosomal lipid enzyme. (J Lipid Res, 2015; https://doi.org/10.1194/jlr.r059220; Structure, 2024; Cell, 2024) (nelson2015physiologicalandpathophysiological pages 10-12, yuan2024structuralandmechanistic pages 1-5, singh2024pld3andpld4 pages 1-3)

Statistics and data from recent studies
- Tissue lipidomics and phenotypes (mouse):
  • Pld4 knockout spleen: ≈80% decrease in BMP; ≈2× increase in several gangliosides (GM3, GD1a, GD2, GT1, GT3); increased lysosomal cholesterol (~1.5×); fewer ILVs; elevated galectin‑3; many defects rescueable by S,S‑BMP. (Cell, 2024; published Nov 27, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8)
  • Partial redundancy/lethality: PLD3/PLD4 double knockout lethality indicates overlapping essential roles in BMP synthesis. (Cell, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8)
- Enzyme biochemistry:
  • Transphosphatidylation synergy: ~3-fold increase in S,S‑BMP production when both 18:1 lyso‑PG and 18:1 MAG are provided at lysosomal pH. (Cell, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 3-5)
  • Nucleic-acid exonuclease specificity: PLD4 cleaves phosphodiester CpG ODN but not phosphorothioates; certain 5′ modifications reduce activity due to the hydrophobic clamp; PLD4 has a lower pH optimum than PLD3. (Structure, 2024; published June 2024; https://doi.org/10.1016/j.str.2024.02.019) (yuan2024structuralandmechanistic pages 23-26, yuan2024structuralandmechanistic pages 14-17)
- Human genetics:
  • SLE association in Japanese GWAS meta-analysis: rs2582511 in the AHNAK2/PLD4 region among 14 significant loci; N=1,363 cases and 5,536 controls; the PLD4 risk allele associates with anti‑dsDNA antibody production. (Ann Rheum Dis, 2019; published April 2019; https://doi.org/10.1136/annrheumdis-2018-214116) (akizuki2019pld4isa pages 1-5)
  • Autoimmune links and heterogeneity: Earlier reviews noted associations with autoimmune traits (RA, SSc), but ancestry-specific differences and negative replication in some cohorts have been reported by later studies, underscoring population heterogeneity in PLD4 associations. (J Lipid Res, 2015; https://doi.org/10.1194/jlr.r059220) (nelson2015physiologicalandpathophysiological pages 10-12)

Biological processes, localization, and pathways
- Where PLD4 functions: The luminal domain operates within endosomes/lysosomes, executing two roles—(i) nucleic-acid degradation to control TLR7/9 ligand availability and (ii) S,S‑BMP synthesis to sustain lysosomal lipid catabolism and intraluminal vesicle dynamics. (Structure, 2024; Cell, 2024) (yuan2024structuralandmechanistic pages 1-5, singh2024pld3andpld4 pages 1-3)
- Pathways:
  • Nucleic acid–sensing pathways: PLD4 restrains TLR7/9 activation by degrading ss nucleic acids in acidifying endolysosomes, thereby limiting downstream NF‑κB/inflammatory signaling. (Structure, 2024; https://doi.org/10.1016/j.str.2024.02.019) (yuan2024structuralandmechanistic pages 1-5)
  • Lysosomal lipid metabolism: PLD4-derived S,S‑BMP is a key cofactor for lipid hydrolases and supports ganglioside/cholesterol catabolism within lysosomes; loss of PLD4 reduces BMP pools and causes secondary lipid storage. (Cell, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 1-3, singh2024pld3andpld4 pages 7-8)

Disease associations and mechanistic links
- Systemic lupus erythematosus (SLE): Genetic association at the AHNAK2/PLD4 locus in Japanese GWAS (rs2582511) correlates with anti‑dsDNA autoantibodies; mouse Pld4 mutants display SLE-like phenotypes (splenomegaly, lymphadenopathy, B‑cell expansion, elevated BAFF, ANA/anti‑dsDNA), providing mechanistic support for PLD4’s role at the intersection of nucleic-acid handling and immune activation. (Ann Rheum Dis, 2019; https://doi.org/10.1136/annrheumdis-2018-214116) (akizuki2019pld4isa pages 1-5)
- Autoimmunity more broadly: Earlier literature linked PLD4 to immune hyperactivation and autoimmune traits including RA/SSc, although effect sizes and replicability vary by ancestry; the recent mechanistic work (nuclease and BMP synthase activities) offers a coherent framework: excess TLR signaling and impaired lysosomal lipid catabolism may cooperate to drive immune dysregulation when PLD4 is deficient or variant. (J Lipid Res, 2015; https://doi.org/10.1194/jlr.r059220; Structure, 2024; Cell, 2024) (nelson2015physiologicalandpathophysiological pages 10-12, yuan2024structuralandmechanistic pages 1-5, singh2024pld3andpld4 pages 1-3)

Therapeutic and translational implications
- Two mechanistic axes emerge:
  1) Nucleic acid–TLR axis: Enhancing PLD4 nuclease function or dampening downstream TLR/type I IFN signaling could mitigate autoimmunity driven by endolysosomal self‑nucleic acids. (Structure, 2024; https://doi.org/10.1016/j.str.2024.02.019) (yuan2024structuralandmechanistic pages 1-5)
  2) Lysosomal lipid axis: Restoring S,S‑BMP levels (e.g., via lipid supplementation, substrate modulation, or enhancing PLD4/PLD3 activity) may correct lysosomal storage phenotypes and organelle dysfunction. Rescue by exogenous S,S‑BMP in PLD-deficient models supports feasibility. (Cell, 2024; https://doi.org/10.1016/j.cell.2024.09.036) (singh2024pld3andpld4 pages 7-8)

Embedded evidence summary
| Topic | Key Finding | Evidence Details (metrics/statistics) | Source (journal, year, DOI) |
|---|---|---|---|
| Identity / Nomenclature | Human PLD4 (gene PLD4), UniProt Q96BZ4; type II membrane with luminal catalytic domain | Luminal domain residues ~60–506 used for structural studies; annotated as PLD family member (UniProt Q96BZ4). (yuan2024structuralandmechanistic pages 23-26) | Structure, 2024; DOI: 10.1016/j.str.2024.02.019 |
| Domain architecture (HKD motifs) | Contains conserved HxKxxxxD/E ("HKD/E") motifs of PLD family | PLD-family split-catalytic HKD/E motifs retained; supports catalytic center formation typical of PLD enzymes. (yuan2024structuralandmechanistic pages 1-5) | Structure, 2024; DOI: 10.1016/j.str.2024.02.019 |
| Subcellular localization | Localizes to endolysosomal/lysosomal compartments as a type II transmembrane protein | Synthesized as type II membrane protein with luminal/extracytosolic catalytic domain trafficked to endolysosomes/lysosomes. (yuan2024structuralandmechanistic pages 23-26, singh2024pld3andpld4 pages 1-3) | Structure, 2024; Cell, 2024; DOIs: 10.1016/j.str.2024.02.019, 10.1016/j.cell.2024.09.036 |
| Enzymatic activity 1: 5'→3' exonuclease | PLD4 acts as an endolysosomal 5'-to-3' exonuclease on single-stranded nucleic acids | Structural + biochemical assays show 5'→3' exonuclease activity on ssDNA/ssRNA; activity degrades CpG ODN and limits endosomal TLR ligand availability. (yuan2024structuralandmechanistic pages 1-5, yuan2024structuralandmechanistic pages 23-26) | Structure, 2024; DOI: 10.1016/j.str.2024.02.019 |
| Enzymatic activity 2: S,S‑BMP synthase | PLD4 (with PLD3) catalyzes synthesis of stereospecific S,S‑BMP via transphosphatidylation (lyso‑PG + MAG) at lysosomal pH | Purified enzymes catalyze S,S‑BMP formation in vitro; PLD4 KO spleen shows ≈80% decrease in BMP levels; enzymatic activity favored at lysosomal pH and with lyso‑PG + MAG substrates. (singh2024pld3andpld4 pages 7-8, singh2024pld3andpld4 pages 1-3) | Cell, 2024; DOI: 10.1016/j.cell.2024.09.036 |
| Substrate specificity (nucleic acid vs lipid; stereoselectivity) | Nuclease activity targets ss nucleic acids (5' end effects); lipid activity uses specific lyso‑PG + MAG species; S,S stereochemistry confers lysosomal stability | PLD4 cannot accommodate certain 5'-modified ssDNA (steric clash); lipid activity shows strong product formation with 18:1 lyso‑PG + 18:1 MAG and produces S,S stereoisomer resistant to lysosomal hydrolysis. (yuan2024structuralandmechanistic pages 23-26, singh2024pld3andpld4 pages 3-5) | Structure, 2024; Cell, 2024; DOIs: 10.1016/j.str.2024.02.019, 10.1016/j.cell.2024.09.036 |
| Structural / mechanistic insights | PLD4 contains a hydrophobic clamp (e.g., L183) that stabilizes substrate/product; captures "link‑and‑release" mechanism and pH-dependent activity differences vs PLD3 | High-resolution structures show intra-chain dimer topology, observed covalent intermediate, and an L183/F423 clamp that restricts substrate access; PLD4 has a lower pH optimum than PLD3. (yuan2024structuralandmechanistic pages 14-17, yuan2024structuralandmechanistic pages 1-5) | Structure, 2024; DOI: 10.1016/j.str.2024.02.019 |
| Pathways: nucleic acid–sensing TLRs | PLD4 limits endolysosomal TLR7/TLR9 activation by degrading nucleic-acid ligands | Biochemical and reporter assays: PLD3/4 nucleolytic activity reduces TLR9-driven NF-κB signalling; loss-of-function increases ligand availability and inflammatory signalling. (yuan2024structuralandmechanistic pages 1-5) | Structure, 2024; DOI: 10.1016/j.str.2024.02.019 |
| Role in lysosomal lipid metabolism | PLD4 is required to maintain BMP pools that facilitate lysosomal lipid degradation; loss causes ganglioside and cholesterol accumulation | KO models show ≈80% BMP reduction in spleen, ~2× accumulation of several gangliosides, ~1.5× increased lysosomal cholesterol, fewer intraluminal vesicles and galectin‑3 recruitment (lysosomal damage marker); many phenotypes rescueable by S,S‑BMP supplementation. (singh2024pld3andpld4 pages 7-8) | Cell, 2024; DOI: 10.1016/j.cell.2024.09.036 |
| Knockout / deficiency phenotypes (mice) | Pld4 mutant mice display autoimmune-like and lysosomal phenotypes | Mouse mutants: low body weight, splenomegaly, lymphadenopathy, B‑cell expansion, elevated BAFF, autoantibodies (ANA, anti‑dsDNA); tissue-specific lipidomic defects match expression (spleen for PLD4). (akizuki2019pld4isa pages 1-5, singh2024pld3andpld4 pages 7-8) | Ann Rheum Dis, 2019; Cell, 2024; DOIs: 10.1136/annrheumdis-2018-214116; 10.1016/j.cell.2024.09.036 |
| Human genetics / disease associations | PLD4 locus associated with SLE in Japanese GWAS; links to anti‑dsDNA and autoimmune traits; other autoimmune associations reported with population heterogeneity | GWAS meta‑analysis (1,363 SLE cases, 5,536 controls) identified AHNAK2/PLD4 region (rs2582511) and association with anti‑dsDNA; other studies report links to SSc/RA but with ancestry-specific results. (akizuki2019pld4isa pages 1-5, nelson2015physiologicalandpathophysiological pages 10-12) | Ann Rheum Dis, 2019; J Lipid Res (review), 2015; DOIs: 10.1136/annrheumdis-2018-214116; 10.1194/jlr.r059220 |
| Recent 2023–2024 advances | Structural resolution (Structure 2024) and lipid‑synthase discovery (Cell 2024) redefine PLD3/4 functions as both exonucleases and lysosomal BMP synthases | Structure (Yuan et al., 2024) elucidates nuclease mechanism; Cell (Singh et al., 2024) demonstrates S,S‑BMP synthase activity with physiological KO phenotypes (lipidomics, rescue experiments). (yuan2024structuralandmechanistic pages 1-5, singh2024pld3andpld4 pages 1-3) | Structure, 2024; Cell, 2024; DOIs: 10.1016/j.str.2024.02.019; 10.1016/j.cell.2024.09.036 |
| Applications / implications | Therapeutic strategies could target TLR/type I IFN hyperactivation or lysosomal lipid pathways (BMP homeostasis) in PLD4 deficiency | Mechanistic data link PLD4 loss to excess TLR signalling and lipid storage phenotypes; BMP supplementation or modulating downstream IFN/JAK signalling are candidate interventions (preclinical rationale). (yuan2024structuralandmechanistic pages 1-5, singh2024pld3andpld4 pages 1-3, akizuki2019pld4isa pages 1-5) | Structure, 2024; Cell, 2024; Ann Rheum Dis, 2019; DOIs as above |


*Table: Concise, citable evidence summarizing identity, domains, localization, dual enzymatic activities, structural mechanisms, pathway roles, knockout phenotypes, human genetics, recent 2023–2024 advances, and therapeutic implications for human PLD4 (UniProt Q96BZ4).*

Conclusion
Collectively, authoritative structural and biochemical studies now define human PLD4 (Q96BZ4) as a lysosomal type II membrane enzyme with dual functions: an acid 5′→3′ exonuclease that regulates endosomal nucleic-acid sensing, and a lipid transphosphatidylase that synthesizes S,S‑BMP, a central cofactor for lysosomal lipid catabolism. Tissue-specific mouse phenotypes, lipidomics, and genetic associations in human cohorts (with population heterogeneity) link PLD4 to autoimmunity and lysosomal dysfunction, providing concrete mechanistic entry points for translational strategies targeting TLR signaling and BMP homeostasis. (yuan2024structuralandmechanistic pages 1-5, singh2024pld3andpld4 pages 1-3, singh2024pld3andpld4 pages 7-8, akizuki2019pld4isa pages 1-5, nelson2015physiologicalandpathophysiological pages 10-12, yuan2024structuralandmechanistic pages 14-17, singh2024pld3andpld4 pages 3-5, yuan2024structuralandmechanistic pages 23-26)

References

1. (yuan2024structuralandmechanistic pages 23-26): Meng Yuan, Linghang Peng, Deli Huang, Amanda Gavin, Fangkun Luan, Jenny Tran, Ziqi Feng, Xueyong Zhu, Jeanne Matteson, Ian A. Wilson, and David Nemazee. Structural and mechanistic insights into disease-associated endolysosomal exonucleases pld3 and pld4. Structure, 32:766-779.e7, Jun 2024. URL: https://doi.org/10.1016/j.str.2024.02.019, doi:10.1016/j.str.2024.02.019. This article has 11 citations and is from a domain leading peer-reviewed journal.

2. (yuan2024structuralandmechanistic pages 1-5): Meng Yuan, Linghang Peng, Deli Huang, Amanda Gavin, Fangkun Luan, Jenny Tran, Ziqi Feng, Xueyong Zhu, Jeanne Matteson, Ian A. Wilson, and David Nemazee. Structural and mechanistic insights into disease-associated endolysosomal exonucleases pld3 and pld4. Structure, 32:766-779.e7, Jun 2024. URL: https://doi.org/10.1016/j.str.2024.02.019, doi:10.1016/j.str.2024.02.019. This article has 11 citations and is from a domain leading peer-reviewed journal.

3. (singh2024pld3andpld4 pages 1-3): Shubham Singh, Ulrich E. Dransfeld, Yohannes A. Ambaw, Joshua Lopez-Scarim, Robert V. Farese, and Tobias C. Walther. Pld3 and pld4 synthesize s,s-bmp, a key phospholipid enabling lipid degradation in lysosomes. Cell, 187:6820-6834.e24, Nov 2024. URL: https://doi.org/10.1016/j.cell.2024.09.036, doi:10.1016/j.cell.2024.09.036. This article has 37 citations and is from a highest quality peer-reviewed journal.

4. (singh2024pld3andpld4 pages 3-5): Shubham Singh, Ulrich E. Dransfeld, Yohannes A. Ambaw, Joshua Lopez-Scarim, Robert V. Farese, and Tobias C. Walther. Pld3 and pld4 synthesize s,s-bmp, a key phospholipid enabling lipid degradation in lysosomes. Cell, 187:6820-6834.e24, Nov 2024. URL: https://doi.org/10.1016/j.cell.2024.09.036, doi:10.1016/j.cell.2024.09.036. This article has 37 citations and is from a highest quality peer-reviewed journal.

5. (yuan2024structuralandmechanistic pages 14-17): Meng Yuan, Linghang Peng, Deli Huang, Amanda Gavin, Fangkun Luan, Jenny Tran, Ziqi Feng, Xueyong Zhu, Jeanne Matteson, Ian A. Wilson, and David Nemazee. Structural and mechanistic insights into disease-associated endolysosomal exonucleases pld3 and pld4. Structure, 32:766-779.e7, Jun 2024. URL: https://doi.org/10.1016/j.str.2024.02.019, doi:10.1016/j.str.2024.02.019. This article has 11 citations and is from a domain leading peer-reviewed journal.

6. (singh2024pld3andpld4 pages 7-8): Shubham Singh, Ulrich E. Dransfeld, Yohannes A. Ambaw, Joshua Lopez-Scarim, Robert V. Farese, and Tobias C. Walther. Pld3 and pld4 synthesize s,s-bmp, a key phospholipid enabling lipid degradation in lysosomes. Cell, 187:6820-6834.e24, Nov 2024. URL: https://doi.org/10.1016/j.cell.2024.09.036, doi:10.1016/j.cell.2024.09.036. This article has 37 citations and is from a highest quality peer-reviewed journal.

7. (nelson2015physiologicalandpathophysiological pages 10-12): Rochelle K. Nelson and Michael A. Frohman. Physiological and pathophysiological roles for phospholipase d. Journal of Lipid Research, 56:2229-2237, Dec 2015. URL: https://doi.org/10.1194/jlr.r059220, doi:10.1194/jlr.r059220. This article has 125 citations and is from a peer-reviewed journal.

8. (akizuki2019pld4isa pages 1-5): Shuji Akizuki, Kazuyoshi Ishigaki, Yuta Kochi, Sze-Ming Law, Keitaro Matsuo, Koichiro Ohmura, Akari Suzuki, Manabu Nakayama, Yusuke Iizuka, Haruhiko Koseki, Osamu Ohara, Jun Hirata, Yoichiro Kamatani, Fumihiko Matsuda, Takayuki Sumida, Kazuhiko Yamamoto, Yukinori Okada, Tsuneyo Mimori, and Chikashi Terao. Pld4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. Annals of the Rheumatic Diseases, 78:509-518, Apr 2019. URL: https://doi.org/10.1136/annrheumdis-2018-214116, doi:10.1136/annrheumdis-2018-214116. This article has 56 citations and is from a highest quality peer-reviewed journal.

## Citations

1. yuan2024structuralandmechanistic pages 1-5
2. nelson2015physiologicalandpathophysiological pages 10-12
3. yuan2024structuralandmechanistic pages 23-26
4. yuan2024structuralandmechanistic pages 14-17
5. https://doi.org/10.1016/j.str.2024.02.019
6. https://doi.org/10.1016/j.cell.2024.09.036
7. https://doi.org/10.1016/j.str.2024.02.019;
8. https://doi.org/10.1194/jlr.r059220;
9. https://doi.org/10.1136/annrheumdis-2018-214116
10. https://doi.org/10.1194/jlr.r059220
11. https://doi.org/10.1016/j.str.2024.02.019,
12. https://doi.org/10.1016/j.cell.2024.09.036,
13. https://doi.org/10.1194/jlr.r059220,
14. https://doi.org/10.1136/annrheumdis-2018-214116,